2026年8月19日 / 美国东部时间上午10:59 / 哥伦比亚广播公司新闻（CBS News）
作者：
梅根·塞鲁洛 《金钱观察》栏目记者
周三早盘，制药商莫德纳股价翻倍，此前该公司宣布其用于治疗黑色素瘤的实验性mRNA疫苗试验取得成功。黑色素瘤是一种致命皮肤癌，预计今年将有超过8500名患者死于该病。
莫德纳及其药物开发合作伙伴默克公司表示，在一项针对高危黑色素瘤患者的研究中，这种新型疗法可防止黑色素瘤复发或扩散。
莫德纳股价在早盘交易中飙升91.52美元，涨幅达145%，至154.48美元，盘中最高触及163美元。默克股价上涨14.35美元，涨幅10.6%，至149.52美元。
这项研究的研究对象为接受过黑色素瘤切除手术的患者，旨在测试该药物降低癌症复发风险的有效性。
试验中，莫德纳的个体化癌症疫苗intismeran与默克的癌症免疫疗法药物Keytruda联合使用。联合用药可更长时间地阻止癌症复发，并防止其扩散至其他器官。
两家制药商计划将尚未发表的研究数据提交给即将召开的国际医学会议的监管机构。
“里程碑时刻”
该研究的首席研究员、悉尼大学黑色素瘤医学肿瘤学与转化研究系主任乔治娜·隆教授周三在一份声明中表示：“今日的研究结果代表了辅助性黑色素瘤治疗领域的一个里程碑时刻。”
隆表示，这项研究首次证明，该疗法可“降低黑色素瘤患者的复发或死亡风险”。
她补充道，这一进展“有可能在辅助性黑色素瘤治疗领域建立新的治疗范式，帮助患者更长时间地保持无癌状态”。
据皮肤癌基金会数据，2026年美国黑色素瘤确诊病例将超过23.468万例。梅奥诊所介绍，黑色素瘤是最致命的皮肤癌类型之一，起源于黑色素细胞——赋予皮肤颜色的细胞，其特征是这些细胞不受控制地增殖。
默克研究实验室院长迪恩·Y·李博士在一份声明中表示：“在许多癌症被认为最易治疗的疾病早期阶段进行干预，术后辅助治疗的目标是为更多患者提高治愈的可能性。”
莫德纳首席执行官斯特凡纳·邦塞尔补充道，这一研究成果堪称“癌症研究领域的关键时刻”。“多年来，为患者个体癌症定制mRNA治疗方案的想法只是一种愿景。我们现在正在帮助将这一愿景变为现实。”
莫德纳的股价仍远低于2021年末和2022年疫情高峰期的水平，当时该公司的新冠疫苗在全球需求推动下股价飙升。
编辑：艾米·皮奇
https://www.cbsnews.com/video/skin-cancer-cases-rising-in-the-us-report-says/
报告：美国皮肤癌病例持续上升
（时长04:40）
Moderna stock more than doubles after melanoma vaccine trial shows “landmark moment”
August 19, 2026 / 10:59 AM EDT / CBS News
By
Megan Cerullo Reporter, MoneyWatch
Drugmaker Moderna’s stock more than doubled on Wednesday morning after the company announced a successful experimental mRNA vaccine to treat melanoma, the deadly skin cancer from which more than 8,500 people are expected to die this year.
Moderna and Merck, its drug development partner, said the novel treatment prevented melanoma from returning or spreading in a study of high-risk melanoma patients.
Shares of Moderna surged $91.52, or 145%, to $154.48 in morning trading after touching an intraday high of $163. Merck’s shares rose $14.35, or 10.6%, to $149.52.
The study, which focused on people who had undergone surgery to remove a melanoma, tested the drug’s efficacy at reducing the risk of the cancer’s return.
The study tested Moderna’s personalized cancer vaccine intismeran in combination with Merck’s Keytruda, its cancer immunotherapy drug. Together, the drugs kept the cancer from returning for longer and prevented it from spreading to other organs.
The drugmakers plan to present the unpublished data to regulators at an upcoming international medical meeting.
“Landmark moment”
“Today’s results represent a landmark moment for adjuvant melanoma treatment,” Professor Georgina Long, the study’s principal investigator and the chair of University of Sydney’s Melanoma Medical Oncology and Translational Research, said in a statement Wednesday.
Long said the study is the first of its kind to show that treatment can “reduce the risk of recurrence or death in patients” with melanoma.
The advancement “has the potential to establish a new treatment paradigm in the adjuvant melanoma setting, helping patients remain cancer-free for longer,” she added.
More than 234,680 cases of melanoma will be diagnosed in the U.S. in 2026, according to the Skin Cancer Foundation. Among the deadliest forms of skin cancer, melanoma starts in melanocytes, the cells that give the skin its color. Melanoma is characterized by the uncontrollable growth of these cells, according to the Mayo Clinic.
“By intervening earlier in the course of disease, when many cancers are considered most treatable, the goal of adjuvant therapy given after surgery is to increase the possibility of cure for more patients,” Dr. Dean Y. Li, president of Merck Research Laboratories, said in a statement.
The findings amount to a “pivotal moment for the field of cancer research,” added Moderna CEO Stéphane Bancel. “For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational. We are now helping turn that vision into a reality.”
Moderna shares are still far from their pandemic-era peak in late 2021 and 2022, when its stock soared on global demand for its COVID-19 vaccine.
Edited by Aimee Picchi
https://www.cbsnews.com/video/skin-cancer-cases-rising-in-the-us-report-says/
Skin cancer cases rising in the U.S., report says
(04:40)
发表回复